Infusion Drug Delivery Articles

1. The Hidden Operational Complexities Of Home Infusion 5/20/2026

   Home infusion can lower costs and improve access, but requires complex coordination, patient readiness, logistics, and monitoring to ensure safe and effective care.

2. Need A Drug Delivery Conversation Starter? Try Target Product Profile 5/18/2026

   In this article, Chief Editor Tom von Gunden explores the need for and existence of cross-functional communication during drug product development and delivery device selection. He consults industry veterans with experience in various formulation or delivery roles at GSK and Merck. They identify the Target Product Profile (TPP) as the core concept guiding collaboration. 

3. Transendocardial Cell Delivery In Post‑Acute Myocardial Infarction 5/4/2026

   Optimized delivery technologies will be central to next-generation therapies, serving as key differentiators for both clinical efficacy and operational feasibility.

4. BCS Class IV: Rescuing Hard To Deliver Molecules With Nanoformulation 4/23/2026

   BCS Class IV drugs have low solubility and permeability. Oral nanoparticles can overcome both barriers, offering a more effective and tunable oral delivery strategy.

5. Patient-Centric Drug Delivery: Do Possible And Preferable Always Align? 4/22/2026

   In this article, Chief Editor Tom von Gunden discusses the alignment of drug delivery method with patient preference and need. He reflects on recent conversations in which he heard from experts in drug and delivery product development, as well as patients themselves, about patient-centric considerations such as safety, efficacy, usability, and convenience. The primary use case is the transition from clinically administered IV to subcutaneous injection, including self-administration.

6. AI, Digitalization, And In Vivo Programming Redefine Cell And Gene Therapy 4/20/2026

   By merging precision genetic engineering with the scalability of nanomedicine and the predictive power of AI, scientists are reshaping the future of human health.

7. Nanosystems And Rare Diseases: Opportunities And Limitations 3/27/2026

   Nanosystems offer unique capabilities, enabling researchers to design precise, versatile delivery systems that address key challenges in rare diseases.

8. Organic Impurities: New Draft ICH Q3E Guidance For Leachables And Extractables 3/17/2026

   A new draft guidance document from ICH, issued jointly with the EMA, adopts the position that the assessment of leachables and extractables requires a holistic framework for risk evaluation.

9. The Future Of Kidney Disease Therapeutics: Bringing Nanomedicine To Nephrology 3/6/2026

   Nanomedicines are solving the drug delivery problem in kidney disease. The next step: bridging the translational gap to advance these technologies into the clinic.

10. The Advantages Of Antibodies Over Ligands In The Alpha Emitter Era 3/5/2026

    The alpha era in radiopharmaceuticals is still being defined. The choices developers make now about delivery platforms will shape individual programs and the trajectory of the field.